Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA.
epidemiology
psoriatic arthritis
spondylitis, ankylosing
Journal
RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
03
11
2022
accepted:
21
02
2023
entrez:
10
3
2023
pubmed:
11
3
2023
medline:
15
3
2023
Statut:
ppublish
Résumé
Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) show certain overlaps: A subset of patients with PsA can develop axial involvement (axial PsA, axPsA), while a subset of patients with axSpA presents with psoriasis (axSpA+pso). Treatment strategy for axPsA is mostly based on axSpA evidence. To compare demographic and disease-specific parameters of axPsA and axSpA+pso. RABBIT-SpA is a prospective longitudinal cohort study. AxPsA was defined based on (1) clinical judgement by rheumatologists; (2) imaging (sacroiliitis according to modified New York criteria in radiographs or signs of active inflammation in MRI or syndesmophytes/ankylosis in radiographs or signs of active inflammation in spine MRI). axSpA was stratified into axSpA+pso and axSpA without pso. Psoriasis was documented in 181/1428 axSpA patients (13%). Of 1395 PsA patients, 359 (26%) showed axial involvement. 297 patients (21%) fulfilled the clinical definition and 196 (14%) the imaging definition of axial manifestation of PsA. AxSpA+pso differed from axPsA regardless whether clinical or imaging definition was used. axPsA patients were older, more often female and less often HLA-B27+. Peripheral manifestations were more often present in axPsA than in axSpA+pso, whereas uveitis and inflammatory bowel disease were more common in axSpA+pso. Burden of disease (patient global, pain, physician global) was similar among axPsA and axSpA+pso patients. AxPsA differs from axSpA+pso in its clinical manifestations, irrespective of whether axPsA is defined clinically or by imaging. These findings support the hypothesis that axSpA and PsA with axial involvement are distinct entities, so extrapolation of treatment data from randomised controlled trials in axSpA should be performed with caution.
Sections du résumé
BACKGROUND
Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) show certain overlaps: A subset of patients with PsA can develop axial involvement (axial PsA, axPsA), while a subset of patients with axSpA presents with psoriasis (axSpA+pso). Treatment strategy for axPsA is mostly based on axSpA evidence.
OBJECTIVES
To compare demographic and disease-specific parameters of axPsA and axSpA+pso.
METHODS
RABBIT-SpA is a prospective longitudinal cohort study. AxPsA was defined based on (1) clinical judgement by rheumatologists; (2) imaging (sacroiliitis according to modified New York criteria in radiographs or signs of active inflammation in MRI or syndesmophytes/ankylosis in radiographs or signs of active inflammation in spine MRI). axSpA was stratified into axSpA+pso and axSpA without pso.
RESULTS
Psoriasis was documented in 181/1428 axSpA patients (13%). Of 1395 PsA patients, 359 (26%) showed axial involvement. 297 patients (21%) fulfilled the clinical definition and 196 (14%) the imaging definition of axial manifestation of PsA. AxSpA+pso differed from axPsA regardless whether clinical or imaging definition was used. axPsA patients were older, more often female and less often HLA-B27+. Peripheral manifestations were more often present in axPsA than in axSpA+pso, whereas uveitis and inflammatory bowel disease were more common in axSpA+pso. Burden of disease (patient global, pain, physician global) was similar among axPsA and axSpA+pso patients.
CONCLUSIONS
AxPsA differs from axSpA+pso in its clinical manifestations, irrespective of whether axPsA is defined clinically or by imaging. These findings support the hypothesis that axSpA and PsA with axial involvement are distinct entities, so extrapolation of treatment data from randomised controlled trials in axSpA should be performed with caution.
Identifiants
pubmed: 36898762
pii: rmdopen-2022-002837
doi: 10.1136/rmdopen-2022-002837
pmc: PMC10008170
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Ann Rheum Dis. 2022 Aug 3;:
pubmed: 35922123
Ann Rheum Dis. 2016 Apr;76(4):701-707
pubmed: 27913376
Ann Rheum Dis. 2021 May;80(5):582-590
pubmed: 33334727
Ther Adv Musculoskelet Dis. 2021 Dec 18;13:1759720X211057975
pubmed: 34987619
Semin Arthritis Rheum. 2021 Aug;51(4):880-887
pubmed: 34198146
Ann Rheum Dis. 2009 Jun;68(6):770-6
pubmed: 19297345
Ann Rheum Dis. 2009 Jun;68(6):777-83
pubmed: 19297344
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
Ann Rheum Dis. 2022 Apr 29;:
pubmed: 35487679
Arthritis Care Res (Hoboken). 2021 Jun;73(6):856-860
pubmed: 32100954
RMD Open. 2020 Feb;6(1):
pubmed: 32209721
Nat Rev Rheumatol. 2022 Dec;18(12):734
pubmed: 36216924
J Rheumatol Suppl. 2021 Jun;97:30-33
pubmed: 34074663
Rheumatology (Oxford). 2020 Jun 1;59(6):1340-1346
pubmed: 31593590
J Rheumatol. 2018 Oct;45(10):1389-1396
pubmed: 29961691
Ann Rheum Dis. 2022 Apr;81(4):466-468
pubmed: 34656991
Ann Rheum Dis. 2022 Apr 29;:
pubmed: 35487678
Z Rheumatol. 2020 Mar;79(2):135-142
pubmed: 30874933
J Clin Med. 2021 Jun 27;10(13):
pubmed: 34199051
Semin Arthritis Rheum. 2021 Apr;51(2):464-468
pubmed: 33774593
Ann Rheum Dis. 2022 Dec;81(12):1678-1684
pubmed: 35973805
Ann Rheum Dis. 2011 Jan;70(1):25-31
pubmed: 21109520
Ann Rheum Dis. 2018 Nov;77(11):1573-1577
pubmed: 30077991
Ann Rheum Dis. 1998 Mar;57(3):135-40
pubmed: 9640127